[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553700":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":27,"acronym":28,"eligibilityCriteria":29,"healthyVolunteers":25,"sex":30,"minAge":31,"maxAge":7,"enrollmentInfo":32,"targetDuration":35,"studyType":36,"phases":7,"briefSummary":37,"conditions":38,"keywords":7,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":7},{"fullName":5,"class":6},"Alberta Health services","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","18F-1007 PSMA PSMA PET\u002FCT","Each patient will receive an IV injection 18F-PSMA-1007 PET\u002FCT.\n\nPET\u002FCT Imaging will be conducted beginning 90-120 minutes after an injection of 4 MBq\u002Fkg (max 400 MBq +\u002F- 15%) 18F-PSMA-1007 in patients.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Denise Chan","CONTACT","403-944-1252","denise.chan@albertahealthservices.ca",{"type":20,"investigatorFullName":21,"investigatorTitle":22,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Dr. Denise Chan","Radiologist","100553700","prostate-cancer-18f-psma-1007-petct-access-trial-100553700",false,"NCT06489496","Prostate Cancer 18F-PSMA-1007 PET\u002FCT Access Trial","PAX","Inclusion Criteria:\n\n1. Age greater than or equal to 18 years.\n2. Able and willing to follow instructions and comply with the protocol.\n3. Provide written informed consent prior to participation in the study.\n4. One of the following:\n\n   * a history of radical prostatectomy for treatment of prostate cancer, and a serum prostate specific antigen (PSA) ≥ 0.2 µg\u002FL\n   * a history of radiotherapy, cryotherapy, or brachytherapy for treatment of prostate cancer, and a serum PSA progressively rising to ≥ 2 µg\u002FL (minimum two samples) OR a serum PSA doubling-time of \\\u003C 9 months\n   * a history of biopsy-proven prostate cancer and high-risk features for metastatic disease prior to treatment with radical prostatectomy, radiotherapy, cryotherapy, brachytherapy, or other similar therapy. High-risk features include a Gleason score ≥ 8, serum PSA \\> 20 µg\u002FL, OR minimum clinical T-stage T3a\n   * patients who do not meet criteria 1-3 but in whom a 18F-PSMA-1007 PET\u002FCT scan is expected to provide clinical benefit as determined by a Urologist, Radiation Oncologist, Medical Oncologist, or Nuclear Medicine physician (licensed in Alberta)\n\nExclusion Criteria:\n\n1. Unable to obtain consent\n2. Age less than 18 years.\n3. Unable to lie flat for 30 minutes to compete PET\u002FCT imaging.\n4. Lack of intravenous access","MALE","18 Years",{"count":33,"type":34},1000,"ESTIMATED","5 Years","OBSERVATIONAL","Primary objective:\n\n• To determine if 18F-PSMA-1007 PET\u002FCT imaging is effective at diagnosing prostate cancers and\u002For metastases compared to conventional imaging \\[including CT, MRI, 99mTc-MDP Bone Scans as available\\].\n\nSecondary Objective:\n\n* To determine safety by evaluating for adverse events\n* To determine which conventional imaging is being performed when 18F-PSMA-1007 PET\u002FCT imaging is available",[39],"Prostate Cancer","NOT_YET_RECRUITING","2024-07-03",{"date":43,"type":44},"2024-07-08","ACTUAL",{"date":46,"type":34},"2024-10-01",{"date":48,"type":34},"2030-10-01",{"name":5,"class":6}]